Skip to main content

Advertisement

SpringerLink
Log in

Serum oxidized low-density lipoproteins in rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to measure serum oxidized low-density lipoprotein (Ox-LDL) levels in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and to identify any association with clinical variables.

Methods

We studied 126 female patients (27 with active RA, 27 with inactive RA, 72 with SLE). One hundred fifteen age-matched healthy women (76 for RA, 39 for SLE) with no clinical or laboratory evidence of disease served as normal controls. Serum Ox-LDL levels were measured with a commercial enzyme-linked immunosorbent assay kit (Mercodia, Sweden).

Results

The serum Ox-LDL levels were significantly higher in patients with active RA (P<0.05) or SLE (P<0.01) than age-matched controls and significantly higher in patients with active RA than with inactive RA (P<0.01). The levels of serum total cholesterol and LDL were significantly lower in patients with RA than in age-matched controls (P<0.01). There was no correlation among serum Ox-LDL levels and inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) or rheumatoid factors in patients with RA.

Conclusions

Compared with healthy women, those with SLE or active RA had increased serum Ox-LDL levels, which may contribute to the increased risk of cardiovascular disease in this patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Symmons DP, Jones MA, Scott DL, Prior P (1998) Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077

    CAS  PubMed  Google Scholar 

  2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494

    CAS  PubMed  Google Scholar 

  3. Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40

    PubMed  Google Scholar 

  4. Banks M, Flint J, Bacon PA, Kitas GD (2000) Rheumatoid arthritis is an independent risk factor for ischemic heart disease. [Abstract.] Arthritis Rheum 43 [Suppl 9]:S385

  5. Gabriel SE, Crowson CS, O’Fallon WM (1999) Comorbidity in arthritis. J Rheumatol 26:2475–2479

    CAS  PubMed  Google Scholar 

  6. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415

    CAS  PubMed  Google Scholar 

  7. Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745

    PubMed  Google Scholar 

  8. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM (1998) PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252

    CAS  PubMed  Google Scholar 

  9. Mertens A, Holvoet P (2001) Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15:2073–2084

    Article  CAS  PubMed  Google Scholar 

  10. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH (2000) Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20:1536–1542

    CAS  PubMed  Google Scholar 

  11. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925

    CAS  PubMed  Google Scholar 

  12. Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GR (1997) Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36:964–968

    Article  CAS  PubMed  Google Scholar 

  13. James MJ, van Reyk D, Tye KA, Dean RT, Cleland LG, Barter PJ (1998) Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipid 33:1115–1121

    CAS  Google Scholar 

  14. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ (1993) Presence of foam cells containing oxidized low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 52:677–680

    CAS  PubMed  Google Scholar 

  15. Dai L, Zhang Z, Winyard PG, Gaffney K, Jones H, Blake DR (1997) A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. Free Radical Bio Med 22:705–710

    Article  CAS  Google Scholar 

  16. Paimela L, Helve T, Leirisalo-Repo M, Vaarala O, Alfthan G, Palosuo T (1996) Clinical significance of antibodies against oxidized low density lipoprotein in early RA. Ann Rheum Dis 55:558–563

    CAS  PubMed  Google Scholar 

  17. Wållberg-Jonsson S, Cvetkovic JT, Sundqvist K-G, Lefvert AK, Rantapää-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882

    PubMed  Google Scholar 

  18. Cvetkovic JT, Wållberg-Jonsson S, Ahmed E, Rantapää-Dahlqvist S, Lefvert AK (2002) Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 41:988–995

    Article  CAS  PubMed  Google Scholar 

  19. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663–669

    CAS  PubMed  Google Scholar 

  20. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69–76

    CAS  PubMed  Google Scholar 

  21. Gitlin JD (1988) Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem 263:6281–6287

    CAS  PubMed  Google Scholar 

  22. Chisolm GM, Hazen SL, Fox PL, Cathcart MK (1999) The oxidation of lipoproteins by monocytes and macrophages. J Biol Chem 274:25959–25962

    Article  CAS  PubMed  Google Scholar 

  23. Kunitake ST, Jarvis MR, Hamilton RI, Kane JP (1992) Binding of transition metals by apolipoprotein A-1 containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A 89:6993–6997

    CAS  PubMed  Google Scholar 

  24. Barnum-Huckins KM, Martinez AO, Rivera EV, Adrian EK Jr, Herbert DC, Weaker FJ (1997) A comparison of suppression of human transferrin synthesis by lead and lipopolysaccharide. Toxicology 118:11–22

    Article  CAS  PubMed  Google Scholar 

  25. Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlën G (1991) Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368

    PubMed  Google Scholar 

  26. Park YB, Lee SK, Lee WK (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704

    CAS  PubMed  Google Scholar 

  27. Situnayake RD, Kitas G (1997) Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56:341–342

    CAS  PubMed  Google Scholar 

  28. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids. Am J Med 89:322–326

    CAS  PubMed  Google Scholar 

  29. Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539

    CAS  PubMed  Google Scholar 

  30. Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887–1893

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy and Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

    Seong-Ho Kim, Chang-Keun Lee, Eun Young Lee, So Yeon Park, You Sook Cho, Bin Yoo & Hee-Bom Moon

Authors
  1. Seong-Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang-Keun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eun Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. So Yeon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. You Sook Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bin Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hee-Bom Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seong-Ho Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, SH., Lee, CK., Lee, E.Y. et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int 24, 230–233 (2004). https://doi.org/10.1007/s00296-003-0358-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-003-0358-4

Keywords

Search

Navigation